Jill Corre

The paper analyzes transcriptomic subtypes in CASSIOPEIA patients to refine the prognostic value of MRD negativity in multiple myeloma, showing varying PFS rates across risk groups.

The paper identifies a therapy-driven genomic double-hit (1pCEN LOH and 1q gain) in relapsed/refractory myeloma, associated with poor prognosis and clonal expansion.

This study identifies CD16/CD226low NK cells with inflammatory signatures and reduced effector functions in multiple myeloma patients, correlating with poor clinical outcomes.

The paper develops a method to identify prognostic copy-number alterations by integrating segmentation and lasso regularization, showing improved recovery of significant regions and survival prediction in multiple myeloma.